Damle N K, Aruffo A
Oncogen Division, Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, WA 98121.
Proc Natl Acad Sci U S A. 1991 Aug 1;88(15):6403-7. doi: 10.1073/pnas.88.15.6403.
Effective stimulation of CD4+ T cells in an immune response depends on activation signals transduced via not only the CD3-T-cell receptor (TCR) complex but also those generated by accessory cell-surface proteins, including some that mediate adhesion between T cells and antigen-presenting cells (APC). Three members of the Ig superfamily, CD54 [intercellular cell adhesion molecule 1 (ICAM-1)], CD58 [lymphocyte function-associated antigen 3 (LFA-3)], and B7, expressed on the surface of APC, have been shown to mediate both adhesion and signaling during T cell-APC interactions. Recently another member of the Ig superfamily, [vascular cell adhesion molecule 1 (VCAM-1; INCAM110)], has been identified. VCAM-1 mediates adhesion between endothelial cells and activated lymphocytes and certain tumor cells. Here, using a soluble VCAM-1 fusion protein with receptor globulin (Rg), we examined the role of VCAM-1 in T-cell activation. We observed that CD4+ T cells, which are inefficiently stimulated by immobilized anti-TCR-1 or anti-CD3 monoclonal antibody (mAb) alone, can be induced to proliferate when exposed to immobilized VCAM-1-Rg in conjunction with either immobilized anti-TCR-1 or immobilized anti-CD3 mAb. The costimulatory effects of VCAM-1-Rg on CD4+T cells is inhibited by mAb to either the CD29 (integrin beta 1)-CD49d [very late activation antigen 4 alpha (VLA-4 alpha)] complex on the surface of CD4+ T cells or to VCAM-1. Stimulation of CD4+ T cells with immobilized VCAM-1-Rg and anti-TCR or -CD3 mAb results in the synthesis of both interleukin 2 (IL-2) receptors and IL-2. In addition, anti-CD25 (anti-IL-2 receptor a) mAb significantly inhibited the VCAM-1-Rg/anti-TCR or -CD3 mAb-driven activation of CD4+ T cells, indicating that endogenously produced IL-2 is in part responsible for the observed T-cell proliferation. Collectively, these results suggest that VCAM-1 can play an important costimulatory role during the activation of CD4+ T cells.
在免疫应答中,对CD4+ T细胞的有效刺激不仅取决于通过CD3-T细胞受体(TCR)复合物转导的激活信号,还取决于辅助细胞表面蛋白产生的信号,其中包括一些介导T细胞与抗原呈递细胞(APC)之间黏附的蛋白。APC表面表达的免疫球蛋白超家族的三个成员,即CD54[细胞间黏附分子1(ICAM-1)]、CD58[淋巴细胞功能相关抗原3(LFA-3)]和B7,已被证明在T细胞与APC相互作用过程中既介导黏附又介导信号传导。最近,免疫球蛋白超家族的另一个成员[血管细胞黏附分子1(VCAM-1;INCAM110)]被鉴定出来。VCAM-1介导内皮细胞与活化淋巴细胞及某些肿瘤细胞之间的黏附。在此,我们使用一种可溶性VCAM-1与受体球蛋白(Rg)的融合蛋白,研究了VCAM-1在T细胞活化中的作用。我们观察到,单独用固定化抗TCR-1或抗CD3单克隆抗体(mAb)刺激效率低下的CD4+ T细胞,当与固定化抗TCR-1或固定化抗CD3 mAb一起暴露于固定化VCAM-1-Rg时,可被诱导增殖。VCAM-1-Rg对CD4+ T细胞的共刺激作用被针对CD4+ T细胞表面CD29(整合素β1)-CD49d[极晚期活化抗原4α(VLA-4α)]复合物或VCAM-1的mAb所抑制。用固定化VCAM-1-Rg和抗TCR或抗CD3 mAb刺激CD4+ T细胞会导致白细胞介素2(IL-2)受体和IL-